Home › Insider buying › RNA

Avidity Biosciences, Inc. (RNA): insider trading, Congress trades & who owns it

By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Insider signal
59/100
Neutral · 90 days
Insider buys
$0
0 buyers · 12 months
Insider sales
$5.3M
8 sellers · 12 months
Funds holding
155
13F · Q2 2026
Congress trades
None
none in 2 years

Avidity Biosciences, Inc. the people running the company have only been selling lately: eight insiders sold about $5.3 million of stock over 12 months, with no open-market purchases.

Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.

155 investment managers listed RNA in their latest 13F filings (Q2 2026); funds were split between buying and selling. Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.

Want the full picture on RNA? Financials, dilution history, a written bull & bear case, top holders and alerts.
See the full RNA report — free account

Latest insider trades in RNA

FiledInsiderRoleTypeSharesPriceValueSource
Jan 23, 2026Hughes Steven GeorgeExecutive OfficerSell2,017$72.45$146KSEC
Jan 23, 2026Hughes Steven GeorgeExecutive OfficerSell2,878$72.45$209KSEC
Jan 23, 2026Boyce SarahCEOSell6,394$72.45$463KSEC
Jan 23, 2026Boyce SarahCEOSell7,993$72.45$579KSEC
Jan 23, 2026Flanagan W. MichaelExecutive OfficerSell2,558$72.45$185KSEC
Jan 23, 2026Flanagan W. MichaelExecutive OfficerSell3,976$72.45$288KSEC
Jan 23, 2026MacLean Michael FCFOSell2,735$72.45$198KSEC
Jan 23, 2026MacLean Michael FCFOSell1,807$72.45$131KSEC
Jan 23, 2026LEVIN ARTHUR ADirectorSell1,758$72.45$127KSEC
Jan 23, 2026McCarthy TeresaExecutive OfficerSell1,476$72.45$107KSEC
Jan 23, 2026McCarthy TeresaExecutive OfficerSell1,453$72.45$105KSEC
Jan 9, 2026Boyce SarahCEOSell8,576$72.23$619KSEC
Jan 9, 2026Calderaro Charles IIIExecutive OfficerSell3,727$72.23$269KSEC
Jan 9, 2026McCarthy TeresaExecutive OfficerSell1,965$72.23$142KSEC
Jan 9, 2026Moriarty John BExecutive OfficerSell2,374$72.23$171KSEC

Questions about RNA

Are insiders buying or selling RNA stock?

In the last 12 months Avidity Biosciences, Inc. insiders made open-market purchases worth about $0 and sales worth about $5.3 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.

When was the last insider trade in RNA?

The most recent open-market insider trade in RNA was filed on 2026-01-23.

How many institutions own RNA?

155 investment managers reported holding RNA in SEC Form 13F filings for Q2 2026.

Has any member of Congress traded RNA?

No congressional trades in RNA were reported in the past two years. The full list is free on CapitalSnitch.

Also active in insider buying

GGRBBDCRBGBPREREFOPTUPRTAN.A.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.

Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).